Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
NCT02335983
Completed
The purpose of the study is to assess the safety, tolerability and activity of a once-weekly regimen of carfilzomib in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2020
Locations: Research Site, Bakersfield, California +58 locations
Conditions: Multiple Myeloma
Register for Updates
Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
NCT00966693
Completed
This phase I/II trial studies the best dose and side effects of lenalidomide and thalidomide, and how well they work with dexamethasone in treating participants with multiple myeloma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as lenalidomide, thalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/12/2020
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
NCT00821249
Completed
This is a 2-phase study during which patients with relapsed or refractory multiple myeloma (MM) or plasma cell leukemia (PCL), who have already received at least two previous treatments, will receive investigational study drug ARRY-520. The study has 3 parts. In the first part of the study, Phase 1, patients will receive increasing doses of study drug, with or without granulocyte-colony stimulating factor (G-CSF) support, in order to achieve the highest dose possible that will not cause unaccep... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2020
Locations: Emory University, Winship Cancer Institute, Atlanta, Georgia +4 locations
Conditions: Multiple Myeloma, Plasma Cell Leukemia
Register for Updates
Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders
NCT02266433
Terminated
The primary objective of this study is to compare local corticosteroid hand and elbow injections to placebo or ketorolac to determine if there is an equal or better reduction of symptoms for common orthopaedic upper extremity disorders including: De Quervain's tenosynovitis, trigger fingers, and tennis elbow (lateral epicondylitis). The investigators will enroll 780 subjects, divided equally into three arms for each disease process, and compare the efficacy of Ketorolac injections to Dexamethaso... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2020
Locations: New York University School of Medicine, New York, New York
Conditions: DeQuervains Tenosynovitis, Lateral Epicondylitis, Tennis Elbow, Trigger Finger, Tenosynovitis, Inflammatory Disease
Register for Updates
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
NCT00553059
Completed
The goal of this clinical research study is to learn if adding dronabinol in combination with the standard of care (dexamethasone and palonosetron) can better help to control nausea and vomiting in patients receiving chemotherapy. The safety of the drug combinations will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2020
Locations: Cancer Research for the Ozarks, Springfield, Missouri +3 locations
Conditions: Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
NCT01483690
Terminated
This is a pilot study using decitabine and vorinostat before and during chemotherapy with vincristine, dexamethasone, mitoxantrone, and peg-asparaginase in pediatric patients with acute lymphoblastic leukemia (ALL).
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
10/05/2020
Locations: Childrens Hospital Los Angeles, Los Angeles, California +27 locations
Conditions: Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia, Precursor T-Cell Lymphoblastic Leukemia
Register for Updates
Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
NCT00017069
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining arsenic trioxide and dexamethasone in treating patients who have recurrent or refractory stage II or stage III multiple myeloma.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/02/2020
Locations: Arizona Clinical Research Center, Tucson, Arizona +9 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02477215
Completed
This Phase I/II study is designed to first identify doses of MLN9708 and bendamustine that are associated with an acceptable adverse event profile when delivered together in 28-day cycles. Additionally, the study aims to assess the efficacy of the combination in patients with relapsed/refractory multiple myeloma. Responders (stable disease or more), will continue to receive up to eight cycles total in the absence of further progressive disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/30/2020
Locations: Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Multiple Myeloma
Register for Updates
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
NCT01248923
Completed
This is a Phase 1 study during which patients with relapsed or refractory multiple myeloma (MM) or plasma cell leukemia (PCL) will receive investigational study drug ARRY-520 and bortezomib, with or without dexamethasone, with granulocyte-colony stimulating factor (G-CSF) support. This study has 2 parts. In the first part, patients will receive increasing doses of study drug (2 dosing schedules will be evaluated) in combination with (1) bortezomib with G-CSF support or (2) bortezomib and dexame... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/28/2020
Locations: Clearview Cancer Institute, Huntsville, Alabama +12 locations
Conditions: Multiple Myeloma, Plasma Cell Leukemia
Register for Updates
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
NCT01104025
Completed
Despite good progress during the last decade, hemophagocytic lymphohistiocytosis (HLH) remains difficult to treat. Two different treatment regimens have been used successfully. The first one, a treatment regimen based on two drugs called etoposide and dexamethasone, has been used worldwide. The second regimen, based on two drugs called Anti-thymocyte globulin (ATG) and prednisone, has been used mostly at one hospital in Paris, for over 15 years. With either regimen, about three quarters of treat... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
09/21/2020
Locations: Phoenix Children's Hospital, Phoenix, Arizona +14 locations
Conditions: Hemophagocytic Lymphohistiocytosis
Register for Updates
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
NCT02709889
Terminated
The primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
09/21/2020
Locations: Banner MD Anderson Cancer Ctr /ID# 155424, Gilbert, Arizona +29 locations
Conditions: Malignant Melanoma, Medullary Thyroid Cancer, Glioblastoma, Neuroendocrine Prostate Cancer, High Grade Gastroenteropancreatic Neuroendocrine Carcinoma, Large-Cell Neuroendocrine Carcinoma, Other Neuroendocrine Carcinoma, Other Solid Tumors
Register for Updates
A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma
NCT01989325
Completed
This is a Phase 2 study during which patients with advanced multiple myeloma will receive either carfilzomib alone (single-agent) or carfilzomib in combination with investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of both single-agent carfilzomib and carfilzomib + filanesib in treating myeloma. Patients will be allowed to crossover from single-agent carfilzomib to carfilzomib + filanesib if disease progression occurs. Approximately 75 pati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/14/2020
Locations: Genesis Cancer Center, Hot Springs, Arkansas +21 locations
Conditions: Advanced Multiple Myeloma
Register for Updates